Gary Wilkinson

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire et al. · Journal of Medicinal Chemistry · 2018 · 313 citations · Full text

Kinase Ataxia Telangiectasia, Cell Death, Molecular Biology +19

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard et al. · European Journal of Cancer · 2019 · 102 citations

Pharmacological Study, Medicine, Immunology +7

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Christian Zurth, Mikko Koskinen, Robert E. Fricke et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2019 · 94 citations · Full text

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Michael Heuser, Neil Palmisiano, Ioannis Mantzaris et al. · Leukemia · 2020 · 54 citations · Full text

Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.

Clifford D. Jones, Kevin Blades, Kevin M. Foote et al. · Cancer Research · 2013 · 37 citations

Molecular Biology, Cancer Patients, Molecular Pharmacology +22